
Zynex Inc (ZYXI) Stock Forecast & Price Target
Zynex Inc (ZYXI) Analyst Ratings
Bulls say
Zynex Inc. demonstrated a promising growth trajectory, with orders increasing by 16% year-over-year in FY2024, suggesting strong market demand for its electrotherapy and pain management products. The company's commitment to innovative technology was underscored by positive results from the NiCo verification clinical study, which highlighted Zynex's laser-based system as superior to traditional pulse oximeters, potentially enhancing its market competitiveness. Furthermore, cost reduction initiatives projected to yield approximately $35 million in annual savings, combined with strategic goals to improve sales rep productivity and product penetration, indicate a robust operational outlook that could drive future revenue growth.
Bears say
Zynex Inc. has indicated a challenging financial outlook, with projected Q1 2025 sales of “at least $30 million,” representing a significant decrease of 37% year-over-year and 35% sequentially, alongside an anticipated EPS loss of $0.30. The company reported Q4 2024 total revenue of $46 million, reflecting a 3% year-over-year decline and falling short of projections, driven by a notable 9% decrease in Device sales. Additionally, the overall business environment is characterized by high competition in the pain management sector and uncertainties regarding regulatory approvals for new products, leading to a revised sales forecast for 2025 of $140 million, a 28% reduction from prior estimates.
This aggregate rating is based on analysts' research of Zynex Inc and is not a guaranteed prediction by Public.com or investment advice.
Zynex Inc (ZYXI) Analyst Forecast & Price Prediction
Start investing in Zynex Inc (ZYXI)
Order type
Buy in
Order amount
Est. shares
0 shares